PLx Pharma Winddown Corp.

OTCPK:PLXP.Q Stock Report

Market Cap: US$30.0

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

PLx Pharma Winddown Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Pat Lonergan

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureno data
CEO ownershipn/a
Management average tenureno data
Board average tenure5.8yrs

Recent management updates

Analysis Article Nov 03

Most Shareholders Will Probably Find That The CEO Compensation For PLx Pharma Inc. (NASDAQ:PLXP) Is Reasonable

Despite strong share price growth of 248% for PLx Pharma Inc. ( NASDAQ:PLXP ) over the last few years, earnings growth...

Recent updates

Seeking Alpha Aug 12

PLx Pharma Non-GAAP EPS of -$0.52 misses by $0.02, revenue of $0.48M

PLx Pharma press release (NASDAQ:PLXP): Q2 Non-GAAP EPS of -$0.52 misses by $0.02. Revenue of $0.48M. Cash & Cash Equivalent Balance of $35.7 Million as of June 30, 2022
Analysis Article May 10

Is PLx Pharma (NASDAQ:PLXP) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article Nov 03

Most Shareholders Will Probably Find That The CEO Compensation For PLx Pharma Inc. (NASDAQ:PLXP) Is Reasonable

Despite strong share price growth of 248% for PLx Pharma Inc. ( NASDAQ:PLXP ) over the last few years, earnings growth...
Analysis Article Sep 23

We're Interested To See How PLx Pharma (NASDAQ:PLXP) Uses Its Cash Hoard To Grow

Just because a business does not make any money, does not mean that the stock will go down. By way of example, PLx...
Seeking Alpha Sep 17

PLx Pharma: First Commercial Launch Makes It Attractive

PLx Pharma has just launched its lead product VAZALORE, the first liquid-filled aspirin capsule. The Company’s PLxGuard drug delivery platform has the potential to be used with other approved or under-development drugs and NSAIDs. The Company has a comfortable cash runway to carry through the VAZALORE manufacturing and distribution while advancing the pipeline for existing and prospective candidates.
Analysis Article Jun 15

PLx Pharma (NASDAQ:PLXP) Is In A Strong Position To Grow Its Business

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, PLx Pharma...
Analysis Article Mar 05

Have Insiders Been Buying PLx Pharma Inc. (NASDAQ:PLXP) Shares?

We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also...

CEO

Pat Lonergan (88 yo)

no data
Tenure

Mr. Patrick M. Lonergan, also known as Pat, co-founded Numark Laboratories Inc. in 1987 and has been its President since January 1989. Mr. Lonergan serves as Member of Chief Executive Officer Advisory Grou...


Board Members

NamePositionTenureCompensationOwnership
Michael Valentino
Chairman12.3yrsUS$393.75k1.62%
$ 0.5
Kirk Calhoun
Independent Director8yrsUS$55.00k0.0055%
$ 0.002
Todd Rosengart
Member of Scientific Advisory Board5.8yrsno datano data
Robert Casale
Independent Director7.7yrsUS$75.50k0.0089%
$ 0.003
Gary Balkema
Independent Director7.7yrsUS$50.00k0.018%
$ 0.005
P. Steg
Member of Scientific Advisory Board5.8yrsno datano data
Deepak Bhatt
Member of Scientific Advisory Board5.8yrsno datano data
Byron Cryer
Member of Scientific Advisory Board5.8yrsno datano data
Jayne Prats
Member of Scientific Advisory Board5.8yrsno datano data
Efthymios Deliargyris
Member of Scientific Advisory Board3.5yrsUS$801.65kno data
Dominick Angiolillo
Member of Scientific Advisory Board5.8yrsno datano data
Carey Kimmelstiel
Member of Scientific Advisory Board5.8yrsno datano data
5.8yrs
Average Tenure
66.5yo
Average Age

Experienced Board: PLXP.Q's board of directors are considered experienced (5.8 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/10/04 06:15
End of Day Share Price 2023/09/29 00:00
Earnings2022/09/30
Annual Earnings2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

PLx Pharma Winddown Corp. is covered by 6 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kenneth TrbovichBrean Capital Historical (Janney Montgomery)
Hamed KhorsandBWS Financial Inc.
Jason ButlerCitizens JMP Securities, LLC